KRAS and non-small cell lung carcinoma: NSCLC patients with SMARCA4/KRAS G12C co-mutations vs. SMARCA4 WT/KRAS G12C mutations had significantly worse OS (4.9 months vs. 11.8 months, HR: 3.07; p < 0.001).